Clinical trial
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating…
NCT00022217 · Matrix Pharmaceutical, Industry · Unknown status
Key facts
| NCT number | NCT00022217 |
|---|---|
| Title | Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer |
| Official title | A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse |
| Lead sponsor | Matrix Pharmaceutical, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, cisplatin-e therapeutic implant, paclitaxel |
| Start date | Nov 1, 2000 |
| First posted | Feb 27, 2004 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: